Research Topics
| Christine Y LuSummaryAffiliation: Harvard University Country: USA Publications
|
Detail Information
Publications
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in AustraliaChristine Y Lu
Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, Massachusetts, USA
Aust New Zealand Health Policy 4:26. 2007..In order to determine how this access system could be improved, the opinions of key stakeholders on access to biological agents for rheumatoid arthritis were explored...- Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007Christine Y Lu
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
BMC Health Serv Res 8:75. 2008..The objective of this research was to update a previous systematic review of interventions, published between 1966 and 2001, to improve the quality and efficiency of medication use in the US managed care setting... - Access to high cost medicines in Australia: ethical perspectivesChristine Y Lu
Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, Massachusetts, USA
Aust New Zealand Health Policy 5:4. 2008..Consideration of ethical aspects of the PBS and similar programs is important in order to achieve the fairest outcomes for individual patients, as well as for the community... - Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based studyChristine Y Lu
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
Clin Ther 33:135-44. 2011..Some Medicaid programs have adopted prior-authorization (PA) policies that require prescribers to request approval from Medicaid before prescribing drugs not included on a preferred drug list... - Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based studyMichael R Law
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
Clin Ther 32:729-41; discussion 716. 2010..However, little is known about the impact of these policies on the use of antihypertensive medicines in the United States... - Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorderChristine Y Lu
Department of Population Medicine, Harvard Medical School, 133 Brookline Ave, 6th Floor, Boston, MA 02215, USA
Psychiatr Serv 62:186-93. 2011..This study examined the association between a Medicaid prior-authorization policy for second-generation antipsychotic and anticonvulsant agents and medication discontinuation and health service use by patients with bipolar disorder... - Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illnessChristine Y Lu
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Med Care 48:4-9. 2010..The objective of this study was to examine the impact of a Maine Medicaid PA policy on initiation and switching of anticonvulsant and atypical antipsychotic treatments among patients with bipolar disorder... - Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?Christine Y Lu
Med J Aust 181:457; discussion 457-8. 2004